Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects

29 ottobre 2014 aggiornato da: Astellas Pharma Europe B.V.

A Phase 1, Single Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects, Including a Drug-drug Interaction Part With Itraconazole

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses of ASP3700 in healthy male subjects. This study will also explore the effect of itraconazole (another drug) on the PK of ASP3700, as well as to evaluate the safety and tolerability of ASP3700 alone and in combination with itraconazole in healthy male subjects.

Panoramica dello studio

Descrizione dettagliata

This study consists of 2 parts: Part 1 is a single ascending dose study where subjects will receive either ASP3700 or matching placebo; Part 2 is a drug-drug interaction (DDI) open-label, crossover study comprised of 1 sequence with 2 investigational periods where subjects will receive ASP3700 alone and in combination with itraconazole.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

44

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Harrow, Regno Unito, HA1 3UJ
        • PAREXEL Early Phase Clinical Unit

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 55 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

Inclusion Criteria:

  • Subject has a body mass index range of 18.5 - 30.0 kg/m2. The subject weighs at least 50 kg.
  • Subject and his female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continue throughout the clinical study period and for 90 days after the final study drug administration.
  • Subject must not donate sperm starting at screening and throughout the clinical study period and for 90 days after the final study drug administration.

Exclusion Criteria:

  • Subject has a known or suspected hypersensitivity to ASP3700 (parts 1 and 2) or itraconazole (part 2 only) or significant adverse reactions to historical cannabinoid use or any components of the formulations used.
  • Subject has any of the liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma-glutamyl transaminase, total bilirubin [TBL]) above the upper limit of normal (ULN). In such a case the assessment may be repeated once (upon admission to the clinical unit).
  • Subject has a history of a suicide attempt or suicidal behavior. Any recent suicidal ideation within the last 3 months or who are at significant risk to commit suicide, as judged by the Investigator using the C-SSRS (a level of 4 or 5) at screening or upon admission to the clinical unit.
  • Subject has any clinically significant abnormality following the Investigator's review of the physical examination, ECG and clinical study protocol-defined clinical laboratory tests at screening or upon admission to the clinical unit.
  • Subject has a pulse rate < 40 or > 90 beats per minute; mean SBP > 140 mmHg; mean DBP > 90 mmHg (vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse rate will be measured automatically) upon admission to the clinical unit.
  • Subject has a mean corrected QT interval using Fridericia's formula (QTcF) interval > 430 ms at day -1. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken.
  • Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit.
  • Subject has a history of drinking more than 21 units of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 3 months prior to admission to the clinical unit.
  • Subject has consumed grapefruit, grapefruit-containing products or Seville orange-containing products within 72 hours prior to admission to the clinical unit.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: ASP3700 single ascending dose cohort
Part 1
oral
Comparatore placebo: Placebo single ascending dose cohort
Part 1
orale
Sperimentale: ASP3700 alone
Part 2
oral
Comparatore attivo: ASP3700 and itraconazole
Part 2
oral
orale

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety as assessed by adverse events (Part 1)
Lasso di tempo: up to end of study visit (up to 16 days)
up to end of study visit (up to 16 days)
Safety as assessed by vital signs (Part 1)
Lasso di tempo: up to end of study visit (up to 16 days)
up to end of study visit (up to 16 days)
Safety as assessed by laboratory tests (Part 1)
Lasso di tempo: up to end of study visit (up to 16 days)
Laboratory tests includes the measurement of sex-hormone related biomarkers and exploratory renal biomarkers.
up to end of study visit (up to 16 days)
Safety as assessed by electrocardiogram (ECG) measurements (Part 1)
Lasso di tempo: up to end of study visit (up to 16 days)
ECG measurements include routine 12-lead ECG, continuous cardiac monitoring (Holter ECG) and real-time cardiac monitoring (ECG telemetry)
up to end of study visit (up to 16 days)
Safety as assessed by Bond and Lader VAS (Part 1)
Lasso di tempo: Up to Day 2
visual analogue scale (VAS)
Up to Day 2
Safety as assessed by C-SSRS (Part 1)
Lasso di tempo: Up to end of study visit (up to 16 days)
Columbia - Suicide Severity Rating Scale (C-SSRS)
Up to end of study visit (up to 16 days)
Safety as assessed by ARCI-49 (Part 1)
Lasso di tempo: Up to Day 2
Addiction Research Center Inventory (ARCI)-49 (49-item)
Up to Day 2
Pharmacokinetic parameter of itraconazole (plasma): Ctrough (Part 2)
Lasso di tempo: Days 3-13
Concentration immediately prior to dosing at multiple dosing
Days 3-13
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): AUCinf (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Area under the concentration-time curve from time of dosing extrapolated to time infinity (AUCinf)
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): AUCinf (%extrap) (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Percentage of AUCinf due to extrapolation from tlast to time infinity (AUCinf [%extrap])
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): AUClast (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast)
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): Cmax (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Maximum concentration (Cmax)
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma):λz (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Terminal elimination rate constant (λz)
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): MRT (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Mean residence time (MRT)
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): tlag (Part 2)
Lasso di tempo: Day 1 (period 1 and 2)
Time prior to the time corresponding to the first measurable (nonzero) concentration (tlag)
Day 1 (period 1 and 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): tmax (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Time of maximum concentration (tmax)
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): t1/2 (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Terminal elimination half-life (t1/2)
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): Vz/F (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Apparent volume of distribution during the terminal elimination phase after extravascular dosing (Vz/F)
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): Aelast (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Cumulative amount of study drug excreted into urine from time of dosing up to the collection time of the last measurable concentration (Aelast)
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): Aeinf (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Cumulative amount of study drug excreted into urine from time of dosing extrapolated to time infinity (Aeinf)
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): Aelast% (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Percentage of study drug excreted into urine from the time of dosing up to the collection time of the last measurable concentration (Aelast%)
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): Aeinf% (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Percentage of study drug excreted into urine from time of dosing extrapolated to time infinity (Aeinf%)
Days 1-7 (period 1) and Days 1-13 (period 2)
Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): CLR (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2)
Renal clearance (CLR)
Days 1-7 (period 1) and Days 1-13 (period 2)
Safety as assessed by orthostatic evaluation (or blood pressure change in orthostatic challenge test) (Part 1)
Lasso di tempo: Up to Day 7
Up to Day 7

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
Composite of pharmacokinetics of ASP3700: AUCinf, AUCinf(%extrap), AUClast, Cmax, CL/F, λz, MRT, tlag, tmax, t½, Vz/F (plasma) (Part 1)
Lasso di tempo: up to Day 7
up to Day 7
Title: Composite of pharmacokinetics of ASP3700: Aelast, Aeinf, Aelast%, Aeinf%, CLR (urine) (Part 1)
Lasso di tempo: up to Day 7
up to Day 7
Safety as assessed by adverse events, vital signs, orthostatic evaluation, laboratory tests, ECG measurements, C-SSRS, Bond & Lader VAS, ARCI-49 (Part 2)
Lasso di tempo: Days 1-7 (period 1) and Days 1-13 (period 2) and at end of study visit (up to 22 days)
Days 1-7 (period 1) and Days 1-13 (period 2) and at end of study visit (up to 22 days)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 maggio 2014

Completamento primario (Effettivo)

1 ottobre 2014

Completamento dello studio (Effettivo)

1 ottobre 2014

Date di iscrizione allo studio

Primo inviato

28 maggio 2014

Primo inviato che soddisfa i criteri di controllo qualità

2 giugno 2014

Primo Inserito (Stima)

4 giugno 2014

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

30 ottobre 2014

Ultimo aggiornamento inviato che soddisfa i criteri QC

29 ottobre 2014

Ultimo verificato

1 ottobre 2014

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

3
Sottoscrivi